Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : J&J Takes New Steps To Manage Doxil Supply During Shortage

share with twitter share with LinkedIn share with facebook
04/05/2012 | 04:48pm EDT
   By Peter Loftus 

Johnson & Johnson (JNJ) said Thursday it would update a rationing program for the cancer drug Doxil to maximize the remaining supply and provide additional treatment cycles to patients already enrolled in the allocation program.

A shortage of Doxil, which treats ovarian and other cancers, emerged last year after J&J's contract manufacturer, Boehringer Ingelheim GmbH's Ben Venue Laboratories unit, experienced production problems. Ben Venue halted production at its Ohio plant in November to address regulatory concerns about contamination; it expects to resume production in late 2012.

No new Doxil has been manufactured, but J&J still has some unused supply to provide to patients under an allocation program created last year to manage the shortage. Some 3,300 patients are in the program.

Beginning Monday, J&J will ask doctors to reconfirm their current allocation for each patient by April 23. If J&J doesn't receive a patient's allocation confirmation or new-supply order by the April 23 deadline, the patient will be removed from the allocation program, J&J said in a notice posted on the Doxil website.

"We want to be sure that physicians reconfirm they continue to need their allocation," said Lisa Vaga, spokeswoman for J&J's Janssen unit, which markets Doxil.

In addition, doctors now have the option to re-enroll patients already in the program, regardless of whether they have completed their prior allocation or continue to receive therapy.

Doctors who determine a patient is receiving a clinical benefit from Doxil may request up to seven cycles of the drug to continue therapy. All requests will continue to be fulfilled on a first-come, first-served basis.

When J&J created the allocation program last year, it allotted up to seven cycles per patient on a first-come, first-served basis. J&J stopped accepting new enrollments after Ben Venue suspended production.

Hundreds of patients were once on a waiting list but J&J said in January it had enough supply to provide to all remaining patients on the list.

J&J, of New Brunswick, N.J., has been able to periodically identify additional supplies of Doxil for various reasons, including some patients having used less Doxil than the amount originally allotted. It is unclear how far the remaining supply will go because J&J doesn't know how much will be requested by doctors or used by patients, Vaga said.

J&J's U.S. Doxil sales plunged 50% to $140 million in 2011 due to the shortage.

In February, the U.S. Food & Drug Administration allowed the temporary importation of Sun Pharma's LipoDox as an alternative to Doxil.

J&J continues to try to restore a reliable Doxil supply, including by switching to another manufacturer.

More information about the latest Doxil supply update can be found at: http://www.doxil.com/doxil-supply-shortage.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
Latest news on JOHNSON & JOHNSON
09:37aJOHNSON & JOHNSON : Stop TB Partnership and Johnson & Johnson, with support from..
09:33aJOHNSON & JOHNSON : Stop TB Partnership and Johnson & Johnson, with support from..
05:06aJOHNSON & JOHNSON : MSF Welcomes Johnson & Johnson Price Cut On Lifesaving TB Dr..
07/06Investor's Can Seize An Opportunity From SANUWAVE'S Acquisition Of Celularity..
07/03JOHNSON & JOHNSON : Vaccine Against Ebola - Commission Grants New Market Authori..
07/02JOHNSON & JOHNSON : Announces European Commission Approval for Janssen's Prevent..
07/02JOHNSON & JOHNSON : European Union Approves Janssen Ebola Vaccine
07/02MERCK : Janssen to Develop Automated Diagnostic Tool for Neglected Tropical Dise..
07/01JOHNSON & JOHNSON : Unit Gets European OK for Preventive Ebola Vaccine
07/01Minerva Neurosciences Opts Out of Agreement With Janssen for Seltorexant
More news
Financials (USD)
Sales 2020 79 551 M - -
Net income 2020 17 872 M - -
Net Debt 2020 4 635 M - -
P/E ratio 2020 21,4x
Yield 2020 2,80%
Capitalization 377 B 377 B -
EV / Sales 2019
EV / Sales 2020 4,79x
Nbr of Employees 132 200
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 161,39 $
Last Close Price 142,98 $
Spread / Highest target 27,3%
Spread / Average Target 12,9%
Spread / Lowest Target -6,98%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-3.36%376 694
ROCHE HOLDING AG5.88%300 494
MERCK & CO., INC.-12.50%200 868
NOVARTIS AG-9.17%195 408
PFIZER, INC.-11.92%191 697
ABBVIE INC.11.83%174 490